美敦力已成功完成对Spr的收购,此举旨在拓宽患者获取微创、非阿片类治疗方案的机会,以应对慢性与急性疼痛。该收购预计将强化美敦力在疼痛管理领域的布局,为临床提供更多样化的治疗选择。
美敦力已成功完成对Spr的收购,此举旨在拓宽患者获取微创、非阿片类治疗方案的机会,以应对慢性与急性疼痛。该收购预计将强化美敦力在疼痛管理领域的布局,为临床提供更多样化的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.